Semaglutide Extended Lifespan in Older Mice
Researchers studied 20-month-old female mice and examined the effects of semaglutide treatment on lifespan and health-related measures.
According to NIH, mice treated with semaglutide until the end of life had a median lifespan nearly 100 days longer than untreated animals. In a separate three-month treatment period, researchers observed improved muscle and cognitive function.
These findings suggest that semaglutide's effects may extend beyond those caused by reduced food intake alone.
Researchers Compared Semaglutide With Calorie Restriction
An important part of the research involved comparing semaglutide treatment with calorie restriction.
Scientists used calorie restriction to examine whether some of the effects seen with semaglutide could simply be explained by reduced food intake.
Over five months, one group of 20-month-old female mice received semaglutide, while another received a diet restricted by 24% that matched the treated animals' feeding pattern. The researchers found similarities between the two approaches, but they also identified differences. Some effects observed in the semaglutide-treated mice could not be explained solely by calorie restriction.
Study Examined Physical and Cognitive Function
The researchers evaluated several aspects of health in the older mice.
Semaglutide treatment was associated with improvements in exploratory behavior, spatial memory and blood-sugar maintenance. Researchers also assessed muscle function.
These findings provide clues about how GLP-1 treatment could affect multiple biological systems at the same time.
Researchers Investigated Biological Aging
The study also looked at changes in gene expression associated with aging.
Researchers found that several hallmarks of natural aging were reduced in treated animals, including increased inflammation and reduced regenerative capacity. The findings suggest that semaglutide may influence processes associated with biological aging.
However, these observations do not establish that the drug slows or reverses aging in humans.
Semaglutide and Calorie Restriction Had Some Different Effects
Although semaglutide and calorie restriction produced several overlapping results, the researchers found important differences between the two groups.
One difference involved metabolic rate. The study found that metabolic rate was reduced in calorie-restricted mice but remained largely unchanged in the semaglutide-treated group.
These differences could help scientists better understand the biological mechanisms involved in GLP-1 treatment.
The Findings Do Not Prove Longer Life in Humans
The study was conducted in mice, which means the findings cannot currently be used to claim that semaglutide extends human lifespan.
Animal research can provide important evidence about biological mechanisms, but effects observed in animals may not necessarily occur in people.
Further research will therefore be needed before scientists can determine whether similar effects could occur in humans receiving GLP-1 medicines.
Why the Research Matters
The study adds to research on whether GLP-1 drugs' broad effects could be linked to aging biology. NIH noted that GLP-1 drugs have delayed the onset of many age-related diseases in animals.
Research into their potential effects on aging could broaden scientists' understanding of how these medicines interact with the body.
The findings provide another area for researchers to investigate, but they remain an early step rather than evidence of an anti-aging treatment.
What Researchers Need to Study Next
Future research will need to determine whether the biological changes observed in mice can also be found in humans.
Clinical studies will be needed to determine the effects of GLP-1 treatment on longevity in people. Future investigations may also examine potential benefits in healthy older individuals.
Researchers will also need to establish which biological pathways are responsible for the differences observed between semaglutide treatment and calorie restriction.
What Happens Next
The findings are likely to encourage further investigation into the broader effects of GLP-1 medicines.
For now, the strongest evidence from this study remains limited to an animal model. Human research will be essential for determining whether the findings have any implications for lifespan or healthy aging in people.
Bottom Line
An NIH-funded study found that semaglutide treatment was associated with a nearly 100-day increase in median lifespan and improvements in several health measures in older healthy female mice. Researchers also identified differences between semaglutide and calorie restriction, suggesting that the drug may affect biological processes beyond reduced food intake. However, the results come from animal research and do not establish that GLP-1 treatment can extend human lifespan.